Bio Path Holdings Inc (BPTH)

[staccani]

'In the in vivo study with PDAC PDX models, combination of BP1003 and gemcitabine caused tumor regression during the 28-day drug treatment period. This anti-cancer activity was maintained for another 21 days, even when drug treatment had ceased'.
The abstract does not tell us how deep the tumor regressions were and in which percantage of the tested mice and if there was any survival improvement versus placebo. I guess it will all depend on the results they will report. $50M market cap for an effective platform to treat all types of cancer is peanuts. Regardless of the short term moves (PPS may go down tomorrow or up , depending on how MM decides to manipulate it, I do not know), this is going much much higher if the technology proves promising in treating all types of cancer as done so far.
The big difference is that this technology allows to deliver more of any drugs due to the fact that directly targets the cancer cells DNA, without affecting the other good cells, hence avoiding all the side effects of normal systemic exposure. This allows to increase enourmously the drug load on target and makes some of the usually non targettable pathways now targettable, in addition to increasing the efficiency of other drugs which target normal targets. In short this could either turn out to be a complete failure or become the investment of the century, and in that case the company could be worth 1,000+ times more than what is worth now.